Effect of verapamil on postischemic "stunned" myocardium: importance of the timing of treatment
K Przyklenk
and
RA Kloner
Department of Internal Medicine, Harper Hospital, Detroit, Michigan 48201.
Timely administration of verapamil has been shown to reduce indexes of ischemic injury in experimental models of prolonged coronary artery occlusion, yet its effect on contractile function of reversibly injured (that is, "stunned") myocardium remains unknown. The objective of the present study was to determine whether verapamil--administered either 30 min before coronary artery occlusion, at the time of reperfusion or 30 min after reperfusion--could attenuate the regional contractile dysfunction and alterations in high energy phosphate metabolism produced by 15 min of transient coronary artery occlusion in anesthetized, open chest dogs. All treatment groups exhibited passive systolic bulging during occlusion. In the control dogs receiving saline solution, segment shortening in the previously ischemic tissue averaged only 31 +/- 8% of normal baseline values after 3 h of reperfusion. In addition, endocardial adenosine triphosphate (ATP) stores were depleted by -8.7 +/- 0.8 nmol/mg cardiac protein to 26.5 +/- 1.1 nmol/mg protein, and endocardial creatine phosphate content increased by 9.6 +/- 4.3 nmol/mg cardiac protein over normal values. Pretreatment with verapamil essentially ablated the phenomenon of postischemic stunning: segment shortening was restored to 115 +/- 8% of normal after 3 h of reflow (p less than 0.01 versus control), endocardial ATP stores were partially preserved (30.6 +/- 1.2 nmol/mg protein; p less than 0.05 versus control) and creatine phosphate overshoot was blunted (endocardial creatine phosphate content decreased by -5.6 +/- 2.9 nmol/mg protein; p less than 0.05 versus control). Verapamil administered at or after reperfusion also attenuated postischemic contractile dysfunction: segment shortening for both groups recovered to 65 +/- 9% of baseline at 3 h after reperfusion (p less than 0.05 versus control). Verapamil given at or after reperfusion had no beneficial effect, however, on high energy phosphate stores. Thus, even when treatment was "delayed," that is, initiated at or after reperfusion, administration of verapamil significantly increased contractile function of the postischemic stunned myocardium.
This article has been cited by other articles:

|
 |

|
 |
 
R. Mandal, V. K. Kutala, M. Khan, I. K. Mohan, S. Varadharaj, A. Sridhar, C. A. Carnes, T. Kalai, K. Hideg, and P. Kuppusamy
N-Hydroxy-pyrroline Modification of Verapamil Exhibits Antioxidant Protection of the Heart against Ischemia/Reperfusion-Induced Cardiac Dysfunction without Compromising Its Calcium Antagonistic Activity
J. Pharmacol. Exp. Ther.,
October 1, 2007;
323(1):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Khoynezhad, Z. Jalali, and A. J. Tortolani
Apoptosis: Pathophysiology and therapeutic implications for the cardiac surgeon
Ann. Thorac. Surg.,
September 1, 2004;
78(3):
1109 - 1118.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gourine, A. Gonon, P.-O. Sjoquist, and J. Pernow
Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium
Cardiovasc Res,
July 1, 2001;
51(1):
100 - 107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ryden, P.-O. Sjoquist, and Q.-D. Wang
Pharmacological tools for the limitation of myocardial reperfusion injury: Experimental evidence
Eur. Heart J. Suppl.,
June 1, 2001;
3(suppl_C):
C28 - C35.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Gross, J. R. Kersten, and D. C. Warltier
Mechanisms of postischemic contractile dysfunction
Ann. Thorac. Surg.,
November 1, 1999;
68(5):
1898 - 1904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bolli and E. Marban
Molecular and Cellular Mechanisms of Myocardial Stunning
Physiol Rev,
April 1, 1999;
79(2):
609 - 634.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Theroux, J. Gregoire, C. Chin, G. Pelletier, P. de Guise, and M. Juneau
Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial
J. Am. Coll. Cardiol.,
September 1, 1998;
32(3):
620 - 628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nordlander, M. Pfaffendorf, and H. B. van Wezel
Calcium Antagonists for Perioperative Blood Pressure Control
Seminars in Cardiothoracic and Vascular Anesthesia,
September 1, 1998;
2(3):
231 - 242.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Rinaldi, A. Z. Linka, N. D. Masani, P. G. Avery, E. Jones, H. Saunders, and R. J. C. Hall
Randomized, Double-Blind Crossover Study to Investigate the Effects of Amlodipine and Isosorbide Mononitrate on the Time Course and Severity of Exercise-Induced Myocardial Stunning
Circulation,
August 25, 1998;
98(8):
749 - 756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Kloner, R. Bolli, E. Marban, L. Reinlib, and E. Braunwald
Medical and Cellular Implications of Stunning, Hibernation, and Preconditioning : An NHLBI Workshop
Circulation,
May 19, 1998;
97(18):
1848 - 1867.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C Smart, K. B Sagar, and D. C Warltier
Differential roles of myocardial Ca2+ channels and Na+/Ca2+ exchange in myocardial reperfusion injury in open chest dogs: relative roles during ischemia and reperfusion
Cardiovasc Res,
December 1, 1997;
36(3):
337 - 346.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C Smart, K. B Sagar, J. E. Schultz, D. C Warltier, and L. R Jones
Injury to the Ca2+ ATPase of the sarcoplasmic reticulum in anesthetized dogs contributes to myocardial reperfusion injury
Cardiovasc Res,
November 1, 1997;
36(2):
174 - 184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Hess and R. C. Kukreja
Free Radicals, Calcium Homeostasis, Heat Shock Proteins, and Myocardial Stunning
Ann. Thorac. Surg.,
September 1, 1995;
60(3):
760 - 766.
[Abstract]
[Full Text]
|
 |
|
|